20 completed, 6 terminated, 3 withdrawn, 2 recruiting. 14 Phase 2, 6 Phase 3, 5 Not applicable, 4 Phase 4, 2 Phase 1.
Follow Grifols Biologicals, LLC: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Clinical Trial to Evaluate Efficacy, Safety, and Pharmacokinetics of Gamunex in Participants With Secondary Antibody Deficiency Associated With Chronic Lymphocytic Leukemia, Multiple Myeloma, or Non-Hodgkin Lymphoma Gamunex-C, 10% Injectable Solution - Chronic Lymphocytic Leukemia, Multiple Myeloma, or Non-Hodgkin Lymphoma | Phase 3 | Recruiting | Grifols Biologicals, LLC | 49 | 2026-05-11 | 2026-10-01 |
| Hepatic Encephalopathy and Albumin Lasting Cognitive Improvement Albumin Infusion - Cirrhosis, Hepatic Encephalopathy | Phase 2 | Active not recruiting | Hunter Holmes Mcguire Veteran Affairs Medical Center | 25 | 2023-11-02 | 2026-08-25 |
| Survey of Human Rabies Immune Globulin Safety in Children Human rabies immune globulin 300 IU/mL - Rabies, Rabies Human | Terminated | The Methodist Hospital Research Institute | 35 | 2023-02-22 | 2025-11-13 | |
| Monotherapy IVIG Gamunex-C for HMG-CoA Reductase Auto-Antibody Positive Necrotizing Myopathy Treatment (The MIGHT Trial) Gamunex-C, Albumin - Immune-Mediated Necrotizing Myopathy | Phase 2 | Withdrawn | University of Washington | 2022-05-01 | 2022-10-24 | |
| ITP Registry and Accompanying Biospecimen Collection Immune Thrombocytopenia | Recruiting | Jena University Hospital | 1100 | 2021-11-29 | 2025-07-15 | |
| Microcirculation Properties of Albumin for Fluid Resuscitation in Septic Shock 20% Albumin, Crystalloid - Sepsis, Severe, Sepsis | Not applicable | Completed | Rachael Cusack | 100 | 2021-09-01 | 2024-10-26 |
| Antithrombin III in Infectious Disease Caused by COVID-19 Antithrombin III - Antithrombin III Deficiency, Covid19 | Phase 2 | Terminated | Enrique Ginzburg | 52 | 2021-07-06 | 2022-09-07 |
| Plasma for Early Treatment in Non-hospitalised Mild or Moderate COVID-19 Patients Convalescent anti-SARS-CoV-2 MBT plasma, Control Group - SARS-CoV-2 Infection, Safety and Efficacy | Phase 2 | Completed | Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia | 384 | 2020-11-10 | 2021-09-08 |
| Preventing Inhibitor Recurrence Indefinitely FVIII, Emicizumab - Hemophilia A, Immune Tolerance | Phase 4 | Unknown | Children's Hospital Los Angeles | 52 | 2020-09-21 | 2023-10-05 |
| Improving Adherence to Rabies PEP Guideline Recommendations Rabies PEP quality improvement bundle - Rabies, Rabies Human | Not applicable | Completed | The Methodist Hospital Research Institute | 70 | 2019-12-29 | 2021-09-05 |
| Study of Infections in Patients With Autoimmune Diseases Treated With Rituximab Autoimmune Diseases | Completed | University Hospital, Lille | 73 | 2019-05-29 | 2026-04-07 | |
| Randomized Placebo Controlled Trial of IVIg in Glycine Receptor Antibody Positive Stiff-person Syndrome Intravenous Immunoglobulins, Human, Placebos - Stiff-Person Syndrome | Phase 3 | Withdrawn | Mayo Clinic | 2018-12-07 | 2019-06-13 | |
| IVIG (Gamunex-C) Treatment Study for POTS Subjects IVIG, Albumin - Postural Tachycardia Syndrome | Phase 1 / Phase 2 | Completed | University of Texas Southwestern Medical Center | 30 | 2018-10-29 | 2024-09-19 |
| Alphanate in Immune Tolerance Induction Therapy Alphanate - Hemophilia A, Congenital | Phase 2 | Terminated | Grifols Therapeutics LLC | 2 | 2018-01-03 | 2021-11-23 |
| The Efficacy Of Intravenous Immunoglobulin Therapy In Treatment Induced Neuropathy Of Diabetes IGIV-C, 0.9% Sodium Chloride - Diabetes Complications, Diabetes Mellitus | Phase 2 | Terminated | Beth Israel Deaconess Medical Center | 13 | 2017-09-11 | 2024-05-07 |
| Ig PRx in AECOPD: Pilot Study Intravenous immunoglobulin (IVIG), Normal Saline - Chronic Obstructive Pulmonary Disease | Phase 2 | Completed | Ottawa Hospital Research Institute | 48 | 2016-09-01 | 2019-11-27 |
| Efficacy and Safety of Plasma Exchange With Albutein® 5% in Participants With Amyotrophic Lateral Sclerosis Albutein 5%, Plasma Exchange - Amyotrophic Lateral Sclerosis | Phase 2 | Completed | Grifols Therapeutics LLC | 12 | 2016-08-29 | 2021-05-05 |
| Microbioma in Sputa From COPD With Alpha-1 Antitrypsin Deficiency collection of sputum - Alpha-1 Antitrypsin Deficiency | Completed | Fondazione Salvatore Maugeri | 100 | 2015-09-01 | 2018-08-01 | |
| Fluid Mobilization in Hospitalized Patients With Acute Kidney Injury (100 ml of Albumin 25%) - Hypotension During Dialysis, Fluid Overload | Phase 4 | Completed | University of California, San Diego | 65 | 2015-06-03 | 2020-08-24 |
| Evaluation Of The Pharmacokinetics Of Antithrombin III In Neonates And Infants Undergoing CPB And ECMO Support Antithrombin III - Extracorporeal Membrane Oxygenation Complication, Cardiopulmonary Bypass | Phase 1 | Completed | Children's Hospital Medical Center, Cincinnati | 27 | 2015-06-01 | 2019-01-25 |
Showing 20 of 33. Sign in to see all of them.
Hemophilia A (6) · Alzheimer Disease (2) · COVID-19 (2) · Plaque, Amyloid (2) · Pulmonary Disease, Chronic Obstructive (2) · Purpura, Thrombocytopenic, Idiopathic (2) · Rabies (2) · Acquired Immunodeficiency Syndrome (1) · Agammaglobulinemia (1) · Amyotrophic Lateral Sclerosis (1) · Antithrombin III Deficiency (1) · Autoimmune Diseases (1) · Brain Diseases (1) · Central Nervous System Diseases (1) · Dementia (1)
Albumins (7) · Immunoglobulins, Intravenous (6) · Antithrombin III (3) · Factor VIII (3) · Saline Solution (3) · Sodium Chloride (3) · factor VIII, von Willebrand factor drug combination (3) · von Willebrand Factor (3) · Hizentra (2) · Immunoglobulins (2) · optivate (2) · Caprylates (1) · Control Groups (1) · Crystalloid Solutions (1) · F8 protein, human (1)
United States (21) · Spain (4) · Canada (3) · India (2) · Bulgaria (1) · France (1) · Germany (1) · Hungary (1) · Ireland (1) · Italy (1) · Poland (1) · Puerto Rico (1) · Russia (1) · Serbia (1)
Ali Khojasteh, MD (1) · Andrew McKeon, MD (1) · Antonio Paez (1) · Christopher Gibbons, MD (1) · Cynthia Bristow, PhD (1) · David Cooper, MD (1) · Edmund Jooste, MD (1) · Enrique Ginzburg (1) · Guy Young, MD (1) · James S Andrews, MD (1) · Jeffrey Alten, MD (1) · Joshua Swan, PharmD, MPH (1) · Juthaporn Cowan, MD, PhD, FRCPC (1)
PMID 30116551, PMID 30499734, PMID 31824943, PMID 33407747, PMID 34887657, PMID 35150610, PMID 35546145, PMID 35867135, PMID 38489186, PMID 39911044, PMID 40020556, PMID 40725675, PMID 41080591, PMID 41892832
2008 (2), 2015 (1)